Clinical Trials | October 09, 2022
Pfizer announces positive topline results from Phase 3 TALAPRO-2 trial
Study achieves primary endpoint of radiographic progression-free survival
Study achieves primary endpoint of radiographic progression-free survival
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
This acquisition will accelerate Medcare's plans to emerge as an international hub for health, beauty, and wellness adding to its existing network of 4 hospitals and over 20 medical centres in the UAE.
The consideration includes Rs. 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an Enterprise Value of Rs. 1,885 crore
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
Transformation to pure-play Innovative Medicines company nears completion
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Azelis’ customers now have access to products including the well-established Polyglykol portfolio, as well as a brand-new range of Motusflex and VitiPure excipients.
Philips FetView will offer real-time, off cart remote patient management with access to data from any ultrasound system
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
Subscribe To Our Newsletter & Stay Updated
